METHODS
Study Design:
• First in human, randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) escalation study enrolling healthy male and female subjects, aged 18 to 55 years. • Eight subjects in each cohort were randomized to receive either APX001 or placebo in a 6:2 ratio, with doses infused over 3 hours (see Methods section above for specific dose levels). • Two sentinel subjects in each cohort received their dose(s) prior to the remaining subjects in the cohort. • A Safety Review Committee reviewed sentinel safety and PK data from the sentinel and remaining subjects to determine the appropriateness of continued dosing and dose escalation, respectively (rules defined a priori in the protocol).
Refer to Methods under Abstract section for details on cohort design and dose levels.
Study Objectives:
• Evaluate the safety, tolerability, and pharmacokinetic parameters of single and multiple doses of APX001 administered by intravenous (IV) infusion in healthy volunteers • Determine the maximum tolerated dose • Explore the safety profile of APX001 in relation to the duration of infusion observed at APX001A target plasma exposures (AUC 0-24 ) required for clinical efficacy • Explore the APX001 dose and dose regimen required to attain APX001A target plasma exposures (AUC 0-24 ) required for clinical efficacy against Candida, Aspergillus and the hard-to-treat rare molds (Scedosporium, Fusarium, and Mucorales) invasive fungal infections
Study Endpoints and Assessments:
• Safety and tolerability: Evaluation of adverse events, physical examinations, vital signs, laboratory safety tests, urinalysis and 12-lead electrocardiograms • Pharmacokinetics: as appropriate -non-compartmental analysis (including AUC 0-24 , AUC 0-t , AUC inf , Cmax, Tmax, CL, t 1/2 ), and compartmental modeling
Stopping Rules:
Dose Escalation Stopping Rule: SRC may recommend to Sponsor that dosing to the next higher dose level in either the SAD or MAD part of the study be suspended if any of the following occur:
• Two subjects experience Grade 3 or 4 AE, including laboratory abnormality per CTCAE Version 4.0 that is considered related to study drug.
This First-In-Human study demonstrated that all doses of APX001 tested were safe and well tolerated. The majority of the adverse events were mild, transitory and resolved without intervention. No dose-limiting toxicities were observed and no AEs or laboratory safety tests met any of the a priori rules that prevented dose escalation. The maximum tolerated dose was not determined/reached in this study. Target APX001A exposures for clinical efficacy against Candida, Aspergillus, and rare molds were exceeded. These drug characteristics suggest that APX001 has potential as a treatment option for patients with life-threatening fungal infections.
Dose Escalation Stopping Rule (continued):
• One subject experiences a Serious Adverse Event (SAE) that is considered related to study drug.
• The opinion of the SRC is that further dose escalation would pose an inappropriate safety risk.
• Should two subjects experience a Grade 2 AE that is classified by the investigator or SRC as nervous system disorder per CTCAE Version 4.0 and considered related to study drug, then dose escalation cannot occur until the AE in question has resolved.
Subject Stopping Rule:
• SAD: Not applicable for the SAD cohorts since subjects receive a single dose.
• MAD: Subjects may be discontinued from the study drug treatment for any AE, SAE, laboratory abnormality, or intercurrent illness which, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the subject. • Accumulation ratios based on Cmax and AUC 0-24 were 1.96 and 5.90, respectively. • The APX001A geometric mean t1/2 was consistent across the SAD and MAD cohorts, with values for MAD Cohorts 7-10 ranging from 52.6 hr to 69.0 hr. 
Parameter

RESULTS
• SAD Cohorts 1-6: After IV infusion of APX001 at single doses from 10 mg to 350 mg, there were dose-proportional increases in the geometric mean APX001A plasma concentrations and values for Cmax, AUC(0-t), and AUC(inf).
Figure 1: Geometric mean plasma concentrations of APX001A after intravenous infusion of APX001 over 3 hours to healthy subjects (SAD Cohorts) -semi-logarithmic axes
• MAD Cohorts 7-10: There was a dose-proportional increase in the geometric mean APX001A plasma concentrations and geometric mean values for Cmax and AUC 0-24 on Days 1, 7, and 14 after IV infusion of APX001 at doses of 50 mg to 600 mg QD x 14 days.
Figure 2: Geometric mean plasma concentrations of APX001A after intravenous infusion of APX001 over 3 hours QD x 14 days to healthy subjects (MAD Cohorts)
• Geometric mean values for t1/2 ranged from 39.2 hr to 74.9 hr for SAD Cohorts 1-6.
• A single APX001 dose of 350 mg maintained drug levels above the MIC of Candida and Aspergillus for one week. 
